An observational study in Obesity, Morbid, sponsored by Istituto Auxologico Italiano. Recruiting at 1 site in Italy. Open to male participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2025-05-13.
Sponsored by Istituto Auxologico Italiano · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 54 studies in Obesity, Morbid with a site in Italy — 11 open to participants now, 12 under way, none of them phase 3. Obesity, Morbid · Italy.
Among the 54 studies in Obesity, Morbid with a site in Italy, this one is the 15th largest by planned enrollment of the 29 observational ones that give a count, is one of 4 that started in 2023, is one of 29 observational ones, reaches primary completion later than 3 of the 11 other live ones, and was the 50th registered.
941 studies on the registry are indexed under Obesity, Morbid; 162 are open to participants now.
Browse Obesity, Morbid studies →11 of the 54 studies in Obesity, Morbid with a site in Italy are open now. Recruiting first, the newest first:
Fondazione Policlinico Universitario Campus Bio-Medico · Sites in Italy
Ages 18–65
Fondazione Policlinico Universitario Agostino Gemelli IRCCS · Sites in Italy
Ages 18–70
Fondazione Policlinico Universitario Agostino Gemelli IRCCS · Sites in Italy
Ages 18–75 · Women only
Istituto Auxologico Italiano · Sites in Italy
Ages 45–65
Istituto Auxologico Italiano · Sites in Italy
Ages 18–65
A study can be open while its sites in Italy have not opened yet or have stopped. Only those recruiting at a site in Italy →
Of the 109 Obesity, Morbid studies recruiting now, 21 (19%) set no upper age limit and 83 (76%) stop at 75 or younger; 8 take children under 18; 9 take healthy volunteers.
This study: 18 Years to 80 Years · male · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
54 studies; the count open now beside each. This study's row is marked.
First in 2005; this study’s year is marked. 4 started in 2023.
This study's planned enrollment of 180 is above the median of 80 across 311 observational studies indexed under Obesity, Morbid.
Median enrollment 80 across the 25 interventional studies, 180 across the 29 observational. Of the 29 that completed or were terminated, 1 (3%) have results posted.
This tab as a report to print or save as PDF → With an account.
3 of 54 have an industry lead sponsor. The 10 most frequent:
Istituto Auxologico Italiano is the lead sponsor of 204 studies on the registry; 70 are open to participants now.
Istituto Auxologico Italiano has 5 studies filed under Obesity, Morbid — fewer than ten, so there is no comparison to draw.
3 of the studies in Obesity, Morbid with a site in Italy that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05781269Istituto Auxologico ItalianoLong Term Effect of Very-low-calories Ketogenic Diet on Weight Control and Cardiovascular Brisk Factors (KETOHEART) | 2026-12-31 |
| NCT06309563Istituto Auxologico ItalianoMetabolic Effects of a Diet Replaced With Essential Amino Acids | 2026-12-31 |
| NCT05917795Fondazione Policlinico Universitario Agostino Gemelli IRCCSEndoscopic Sleeve Gastroplasty With Endomina® for the Treatment of Obesity in Kidney Transplant Candidates | 2027-07-01 |
Add all 3 to your calendar (.ics) → With an account.
Among the 54 studies in Obesity, Morbid with a site in Italy, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The aim of this observational study is to evaluate the actual secretion of cortisol and testosterone in obese male subjects, together with the receptor sensitivity to these hormones in order to understand whether the hormonal milieu deriving from these parameters is associated with alterations in bone metabolism, lipoprotein concentration and function, and/or the severity and complications of obesity.
It will be also investigated if this hormonal milieu is a predictive factor for cardiovascular disease in obese patients.
Eligible subjects are male patients (age 18-80 years) with severe obesity and no other known causes of hypercortisolism or hypogonadism.
Questionnaires for the evaluation of mood and symptoms will be collected upon enrollment, patient's anamnestic and clinical data relating to disease complications, BMI, previous blood tests, cortisol suppression with dexamethasone 1 mg will be collected, and blood sample will be sent to and analyzed at a centralized laboratory for the study of Steroid hormones, bone metabolism, lipoprotein function, genetics and receptor analysis.
Patients affected with severe obesity
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Association of androgen milieu with the severity of obesity
Evaluate the association of hypogonadism and/or androgen receptor polymorphisms that reduce sensitivity to androgens with: patients' BMI; comorbidities of obesity, and bone metabolism
Time frame: 2024
Association of cortisol milieu with the severity of obesity
Evaluate the association of hypercortisolism and/or glucocorticoid receptor polymorphisms that increase sensitivity to cortisol with: patients' BMI; comorbidities of obesity, and bone metabolism
Time frame: 2024
Algorithm fo CV risk in obesity
Use of artificial intelligence methods to hypothesize an algorithm including steroid milieu that can identify obese patients at greater cardiovascular risk
Time frame: 2024
Prevalence of hypogonadism in morbid obesity
To evaluate the prevalence of hypogonadism in patients with severe obesity using EMAS criteria
Time frame: 2024
Prevalence of patients with morbid obesity unresponsive to overnight suppression test
To evaluate the prevalence of patients with severe obesity positive to Nugent testing
Time frame: 2024
Enrichment in rare HH variants in obese patients with central hypogonadism
Compare the enrichment in rare variants for HH-associated genes in obese patients with hypogonadotropic hypogonadism, compared to the general population
Time frame: 2025
Enrichment in rare variants associated with hypercortisolism in obese patients unresponsive to Nugent testing
Compare the enrichment in rare variants in genes associated with hypercortisolism in obese patients unresponsive to Nugent testing, compared to the general population
Time frame: 2025
Started May 2023 (actual). Primary completion is estimated for Jun 2026, 37 months after the start.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Istituto Auxologico Italiano →